The study has been carried out to determine diagnostic and therapeutic pathways in a group of HF diabetic patients and to verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy.
406 patients affected with heart failure and Type 2 Diabetes Mellitus, referred to Cardiologists and Diabetologists of pertaining healthcare districts in Campania, and followed for at least one year between 2018 and 2019, were enrolled in this retrospective study and divided in Group A, composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (\>45%) and Group B, formed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%). All patients had performed periodic clinical evaluations and an echocardiographic exam every 12 months. Anthropometric parameters, HF etiology, co-morbidities, complications and ongoing therapies were collected.
Study Type
OBSERVATIONAL
Enrollment
406
Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Federico II University
Naples, Italy
Total Cholesterol, LDL, HDL Triglycerides, Creatinine
mg/dl
Time frame: 12 months
B-type natriuretic peptide (BNP)
pmol/m
Time frame: 12 months
HbA1c
mmol/L
Time frame: 12 months
Ejection Fraction
Time frame: 12 months
Left Ventricular End-Diastolic Volume Index (LV-EDVi), Left Ventricular End-Systolic Volume Index (LV-ESVi), Left Atrial Volume Index (LAVi)
ml/m2
Time frame: 12 months
E velocity, A velocity,E' velocity
m/sec
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.